JP2024519196A5 - - Google Patents
Info
- Publication number
- JP2024519196A5 JP2024519196A5 JP2023564487A JP2023564487A JP2024519196A5 JP 2024519196 A5 JP2024519196 A5 JP 2024519196A5 JP 2023564487 A JP2023564487 A JP 2023564487A JP 2023564487 A JP2023564487 A JP 2023564487A JP 2024519196 A5 JP2024519196 A5 JP 2024519196A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- seq
- composition according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178750P | 2021-04-23 | 2021-04-23 | |
| US63/178,750 | 2021-04-23 | ||
| PCT/EP2022/060669 WO2022223770A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of cutaneous lupus erythematous |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519196A JP2024519196A (ja) | 2024-05-09 |
| JP2024519196A5 true JP2024519196A5 (https=) | 2024-12-02 |
Family
ID=81850041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564487A Pending JP2024519196A (ja) | 2021-04-23 | 2022-04-22 | 皮膚エリテマトーデスの処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002589A1 (https=) |
| EP (1) | EP4326322A1 (https=) |
| JP (1) | JP2024519196A (https=) |
| KR (1) | KR20240000557A (https=) |
| CN (1) | CN117222430A (https=) |
| AU (1) | AU2022261422A1 (https=) |
| BR (1) | BR112023021868A2 (https=) |
| CA (1) | CA3216390A1 (https=) |
| IL (1) | IL307750A (https=) |
| TW (1) | TW202317617A (https=) |
| WO (1) | WO2022223770A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| GB202315831D0 (en) * | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662381B2 (en) * | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| TW202237647A (zh) * | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
-
2022
- 2022-04-22 CA CA3216390A patent/CA3216390A1/en active Pending
- 2022-04-22 EP EP22725714.4A patent/EP4326322A1/en active Pending
- 2022-04-22 BR BR112023021868A patent/BR112023021868A2/pt unknown
- 2022-04-22 TW TW111115528A patent/TW202317617A/zh unknown
- 2022-04-22 CN CN202280029637.6A patent/CN117222430A/zh active Pending
- 2022-04-22 AU AU2022261422A patent/AU2022261422A1/en active Pending
- 2022-04-22 IL IL307750A patent/IL307750A/en unknown
- 2022-04-22 WO PCT/EP2022/060669 patent/WO2022223770A1/en not_active Ceased
- 2022-04-22 KR KR1020237040112A patent/KR20240000557A/ko active Pending
- 2022-04-22 JP JP2023564487A patent/JP2024519196A/ja active Pending
-
2024
- 2024-02-07 US US18/435,476 patent/US20250002589A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4114465B1 (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| JP2024519196A5 (https=) | ||
| US20250051453A1 (en) | Methods for treating bullous pemphigoid using fcrn antagonists | |
| JP2024518735A5 (https=) | ||
| JP2024530954A5 (https=) | ||
| JP2023546361A5 (https=) | ||
| KR20250039317A (ko) | 아토피성 피부염의 치료를 위한 il-13 항체 | |
| US20250002589A1 (en) | Treatment of cutaneous lupus erythematous | |
| JP2024543509A5 (https=) | ||
| JP2024516886A5 (https=) | ||
| JP2024527001A5 (https=) | ||
| JP2024516886A (ja) | 全身性エリテマトーデス患者における１型インターフェロン受容体阻害剤のステロイド節約 | |
| Choi et al. | Suppressive effects of long-term treatment with inhaled steroids on hypothalamic-pituitary-adrenal axis in asthma | |
| TW202340245A (zh) | 狼瘡之治療 | |
| US20120142605A1 (en) | Methods of treating psoriasis | |
| CN117337305A (zh) | 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制 | |
| EA052183B1 (ru) | Лечение кожной красной волчанки | |
| CN117677638A (zh) | 狼疮的治疗 | |
| HK40087032A (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| HK40087032B (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| Baba et al. | Issues associated with stepwise management of bronchial asthma | |
| RU2024118893A (ru) | Комбинированная терапия, включающая антитело к il-23 и кортикостероид, для лечения псориаза | |
| CN117157099A (zh) | 用于皮下注射的抗ifnar1给药方案 | |
| Divers | Use of Corticosteroids in Equine Practice |